Isis Pharmaceuticals, Inc. (ISIS)
-NasdaqGS | Prev Close: | 20.46 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 16.83 |
|---|
| Beta: | 1.69 |
|---|
| Next Earnings Date: | 7-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 7.56 - 23.03 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 1,627,800 |
|---|
| Market Cap: | 2.12B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.43 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Isis Pharmaceuticals' Management Presents at UBS Global Healthcare Conference (Transcript)at Seeking Alpha(Mon, May 20)
- Presentation Pandemonium Equals 30% Popat Motley Fool(Fri, May 17)
- A Disconnect Between Future Prospects of Drug Candidates Versus Where Share Price is Currently Trading: Portfolio Manager Finny Kuruvilla Discusses the Biotech and Pharmaceutical SectorsWall Street Transcript(Thu, May 16)
- The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis PharmaceuticalsZacks(Thu, May 16)
- ISIS Pharmaceuticals Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Wed, May 15)
- Sanofi/REGN Commence EnrollmentZacks(Wed, May 15)
- Isis Gets $3.5M Milestone PaymentZacks(Tue, May 14)
- ISIS PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 14)
- Celgene Attains 52-Week HighZacks(Tue, May 14)
- Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare ConferencePR Newswire(Mon, May 13)
- 1 Biotech's Surprise Dilution Decodedat Motley Fool(Sun, May 12)
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Fri, May 10)
- 6 Superstars For Your Biotech Portfolio: John McCamantat Seeking Alpha(Fri, May 10)
- Snag ISIS Even Lower Than Its Secondary?at Forbes(Fri, May 10)
- Isis Pharmaceuticals Earns $3.5 Million from Biogen IdecPR Newswire(Thu, May 9)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| ISIS | 0.00% | 2.12B |
| NVO | 0.00% | 92.98B |
| TEVA | 0.00% | 34.24B |
| AGN | 0.00% | 29.20B |
| FRX | 0.00% | 10.11B |
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 17.38 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.76 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.23 |
|---|
| Mean Recommendation*: | 2.6 |
|---|
| PEG Ratio (5 yr expected): | -0.88 |
|---|
Business Summary
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The companys flagship product, KYNAMRO injection, is an apo-B synthesis inhibitor for patients with homozygous famili...
View More